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A wealth of evidence accumulated over the last two decades has unambiguously 
linked lipid rafts to neurodegenerative diseases, in particular to Alzheimer’s disease 
(AD). These microdomains are highly dynamic membrane platforms with differ-
entiated physicochemical and molecular properties compared to the surrounding 
membrane microenvironment, and are the locus for a number of central processes in 
neuronal physiology. Most recent evidence pinpoint to lipid rafts as main players in 
AD neuropathology. It is now widely accepted that lipid rafts actively participate 
in the processing of amyloid precursor protein to generate amyloid beta peptides, a 
main component of amyloid plaques. Current evidence have highlighted the exis-
tence of severe alterations in the molecular structure and functionality of lipid rafts 
in the frontal cortex of human brains affected by Alzheimer’s disease. An exception-
ally interesting observation is that lipid raft destabilization can be demonstrated 
even at the earliest stages of AD neuropathology. In the present review, we will first 
elaborate on the structure and function of these multifaceted subcellular structures 
and second to focus on the impact of their alterations in neuronal pathophysiology 
along the onset and progression of AD continuum.
Keywords: membrane microdomains, lipid rafts, membrane neurochemistry, 
lipid-protein interactions, lipid raft biophysics, lipid raft aging, neurodegeneration, 
Alzheimer’s disease (AD)
1. Lipid rafts: definition and significance
Our current view of cell membranes is far from the historical view of a being 
floating mixture of lipids and proteins mixed uniformly in the form of bilayers. 
Instead, evidence accumulated in the last three decades has revealed that membrane 
constituents can segregate to form discrete domains. The heterogeneous structures 
of membrane lipids provide them the ability to mix non-randomly in the bilayer 
and to form specific lipid microdomains. The best characterized class of these 
structural entities has been termed ‘lipid rafts’ which are featured by their higher 
contents of cholesterol and sphingolipids compared to their surroundings. Despite 
some controversies on a proper definition for lipid rafts, in 2006, at the Keystone 
Symposium on Lipid Rafts and Cell Function, it was agreed that “membrane rafts 
are small (10–200 nm), heterogeneous, highly dynamic, sterol, and sphingolipid-
enriched domains that compartmentalize cellular processes. Small rafts can 
sometimes be stabilized to form larger platforms through protein–protein and 
protein-lipid interactions” [1].
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Lipid rafts have been found in most cell types, from epithelial cells to neurons, 
and share essential chemical and physical properties, but differ in specific compo-
nents, mainly proteins, which are responsible for functional heterogeneity of cell 
types, populations or even developmental stages.
The importance of lipid rafts in nerve cells lays in the fact that they behave as 
functional platforms which participate in a number of physiological processes 
involved in signal transduction, such modulation of receptor activities, protein 
interactions in transduction cascades, and the function of ion channels, but also in 
dendritic and axonal protein trafficking and sorting, regulation of neurotransmitter 
receptors and in the exocytotic neurotransmitter release, posttranslational modifi-
cations of proteins and lipids, and in many aspects related to cell-to-cell communi-
cation, including multifaceted synaptic physiology [2–4].
The agreement exist that these microdomains are highly dynamic structures 
providing transient and fluid architectural scaffolding platforms, which by under-
going structural and functional changes they accomplish a variety of functions in a 
coordinated intracellular and extracellular context. Remarkably, current evidence 
demonstrate they lipid rafts may also play significant roles in different pathological 
conditions. Thus, lipid rafts and raft components are key players in a variety of 
pathological events, i.e. by facilitating conversion of prion protein (PrPc) to its 
infectious scrapie form (PrPsc) [5], by regulation of Amyloid Precursor Protein 
processing in Alzheimer’s disease [6], by expressing binding sites for toxins inter-
nalization such cholera toxin [7] or by providing specific entry pathways for various 
types of viruses and budding of mature virions from infected cells [8, 9] including 
the HIV-1 or the SARS-CoV-2 which is driving us mad, towards an unprecedented 
global chaos (by providing attachment of S-protein to ACE2 and other auxiliary 
proteins clustered in lipid rafts) [9], amongst other pathological processes. During 
the last decade, investigation on lipid rafts biology has received enormous atten-
tion due to the demonstration of its involvement in neurodegenerative diseases, in 
particular in Alzheimer’s disease, as we will discuss later.
2. Biochemical and biophysical structure of lipid rafts
Besides being enriched in cholesterol and sphingolipids, lipid rafts are also 
endowed with a particular lipid signature, which makes them different from 
other domains in the non-raft membrane plane. Such differences are illustrated 
in Figure 1 for membrane raft and non-raft fractions in the gray matter of human 
frontal cortex. As can be observed, compared to bulk non-raft membranes, lipid 
rafts contain higher contents of saturated fatty acids, lower levels of mono- and 
polyunsaturated fatty acids, and nearly all of the cellular contents of sphingomyelin, 
cerebrosides and sulfatides.
According to the polar head group, sphingolipids are divided in two major 
phosphosphingolipids such sphingomyelin, and glycosphingolipids which includes 
gangliosides, cerebrosides and sulfatides. Ceramide serves as the backbone to generate 
sphingolipids to produce sphingomyelin or more complex glycosphingolipids after 
incorporation of phosphocholine or sugars at the hydroxyl group. Both classes of 
sphingolipids, phosphosphingolipids and glycosphingolipids, are major components 
of lipid rafts and display pleiotropic behaviors affecting a number of essential func-
tions associated with normal and pathological states, particularly in AD [10–12].
Gangliosides are acidic glycosphingolipids containing one or more sialic acid 
residues, representing about 6% of total lipids, and particularly abundant in 
raft-like lipid microdomains of neuronal cells [12, 13]. They are concentrated in the 
outer leaflet of the plasma membrane (Figure 2), where they are anchored by the 
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Figure 1. 
Comparative analyses of lipid rafts and non-raft domain in the gray matter of human frontal cortex. 
(A) Lipid classes. LPC: Lysophosphatidylcholine, SM: Sphingomyelin, PC: Phosphatidylcholine, PS: 
Phosphatidylserine, PI: Phosphatidylinositol, PG: Phosphatidylglycerol, PE: Phosphatidylethanolamine, 
DAG: Diacylgycerides, CHO: Cholesterol, FFA: Free fatty acids, TG: Triacylglycerides, SE: Sterol esters. 
(B) Main fatty acid groups. DMA: Dimethylacetals, LCPUFA: Long-chain polyunsaturated fatty acids, PI: 
Peroxidability index, UI: Unsaturation index. (C) Distribution of protein markers in fractional separation 
of cell membranes. Fractions 1 and 2 correspond to lipid rafts while fraction 6 is mainly composed by non-raft 
membranes. (D) Score plots of lipids (fatty acids) resulting from multivariate analyses on membrane domains 
from mouse cortex illustrating the lipid fingerprints of raft and non-raft domains.
Figure 2. 
Schematic representation of the lipid raft membrane structure. For details see the text.
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hydrophobic ceramide part of their molecule while the oligosaccharide chain pro-
trudes into the extracellular medium. Main gangliosides in the brain are GM1 and 
GDs (GD1a in a-series, and GD1b and GT1b in b-series) [11]. They participate in 
the two-dimensional and transverse structuration of the membrane, lipid– protein 
interactions and organization of lipid rafts [13, 14]. The high heterogeneity of oli-
gosaccharide structures in gangliosides allows specific interactions with a diversity 
of molecules at the surface of cell membrane [10, 13, 14]. “Cis” and “trans” interac-
tions of gangliosides play multiple roles in infectious diseases [15] where they act 
as cellular receptors and coreceptors for viruses, bacteria, and microbial toxins. 
Prominent examples are GM1 as the receptor for Vibrio cholerae toxin ( cholera 
toxin), for Clostridium botulinum toxin (botulinum toxin), and for the SabA adhesin 
of Helicobacter pylori [15, 16]. Further, as we will discuss later, gangliosides are 
important regulators of amyloid β toxicity in Alzheimer’s disease by modulation of 
polymerization of peptide species [17].
Lipid rafts biogenesis occurs in the trans-Golgi network, where their composi-
tion is set and the resulting vesicles fused to the plasma membrane. One remarkable 
characteristic lipid profile of lipid rafts in nerve cells is that, with the exception 
of gangliosides, sulfatides and sphingolipids, most lipid classes and fatty acids 
are present in significant amounts in raft and non-raft domains, but they differ 
substantially in their relative contents (Figure 1A). Triglycerides and free fatty 
acids are totally excluded from either domain. As a general rule, sphingolipids are 
more abundant in lipid rafts fraction and glycerophospholipids (or phospholipids) 
are more abundant in non-rafts fractions (Figure 1A). Amongst phospholipids, 
neutral phospholipids, phosphatidylethanolamine (PE) is the most abundant 
phospholipids in lipid rafts, while phosphatidylcholine (PC) and anionic phos-
pholipids phosphatidylserine (PS) and phosphatidylinositol (PI) are present in 
significant proportion though less abundant than in non-raft domains. The pres-
ence of anionic phospholipids is paramount for neuronal physiology as they serve 
as sources for intracellular messengers and bioactive lipid mediators, i.e. inositol 
phosphates, diacylglycerol, eicosanoids (such prostaglandins and leukotrienes) and 
docosanoids (such Neuroprotectin D1) [17–22]. Fatty acids are also heterogeneously 
distributed between rafts and non-rafts, with saturates containing acyl chains of 16 
or more carbon atoms being particularly abundant in lipid rafts. Monounsaturated 
(monoenes) and polyunsaturated fatty acids of the n-3 (mainly docosahexae-
noic acid, DHA) and n-6 (mainly arachidonic acid, AA) series, are present at 
 significantly lower amounts compared to non-rafts (Figure 1B).
DHA and AA are essential components of nerve cells membranes which esterify 
the sn-2 position of glycerophospholipids (mainly phosphatidylethanolamine and 
phosphatidylserine, the most abundant phospholipids in nerve cells). In cerebral 
gray and white matter, phosphoglyceride classes PE, PC, PS, PG and PI have 
distinctive LCPUFA profiles. Thus, ARA greatly exceeds DHA in phosphatidylino-
sitol, whereas DHA exceeds ARA in phosphatidylserine. Brain phospholipids also 
include plasmalogens, which contain a vinyl-ether and an ester bond at the sn-1 and 
sn-2 positions, respectively [23]. As with conventional phospholipids, plasmalogens 
are classified according to their head group in the sn-3 position, the most abundant 
plasmalogens being plasmenyl-ethanolamine (PlsEtn) and plasmenyl-choline 
(PlsCho). The sn-2 position of PlsEtn and PlsCho display preferential esterification 
by LCPUFAs, a fact whereby plasmalogens are considered important LCPUFAs 
reservoirs of in nerve membranes.
Overall, differences in the lipid fingerprint of raft and non-raft domains 
(Figure 1A and B) are sufficiently different as to allow the complete discrimination 
of membrane domains based on a multivariate approach (Figure 1D). It turns out 
that saturated long acyl chains of phospholipids and especially sphingolipids, allow 
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tight intermolecular packing through hydrophobic interactions within the bilayer, 
providing differentiated lipid complexes in juxtaposition with kinked unsaturated 
acyl chains of bulk membrane phospholipids. Raft lipids are held together by 
relatively weak non-covalent bonds, establishing a dynamic equilibrium of raft 
and non-raft regions in the plasma membrane. In the case of sphingolipids, these 
molecules interact laterally through van der Waals interactions and hydrogen bonds 
between their sphingosine backbones. Further, as the majority of sphingolipids 
contain long saturated acyl chains, their tighter intramembrane packing with 
associated lipids allows the formation of stable gel–liquid phase which lead to 
laterally segregation of sphingolipid-rich domains from their glycerophospholipid-
rich surroundings [24, 25]. Structurally, this degree of lateral association is further 
increased by the incorporation of cholesterol, whose planar sterol ring interacts 
with the saturated acyl chains [26].
One key difference between phospholipids and sphingolipids is the length and 
saturation of their acyl chains. These acyl chains are always saturated and longer in 
sphingolipids than in phospholipids and allow hydrophobic interactions between 
the two leaflets of the bilayer [27, 28]. These molecular attributes are directly 
implicated not only in the formation of domains enriched in sphingolipids, but also 
in the coupling between the two leaflets in the rafts by interdigitation of the very 
long chain fatty acid between exoplasmic and cytoplasmic leaflets (Figure 2) and 
by augmenting hydrogen bonding in sphingolipid-sterol rich domains [28, 29]. 
This particularity is very important because it implies that lipid rafts exist as stable 
bilayer structures [28]. Hydrophilic interactions between phospholipid head groups 
are also critical as they provide physical forces for raft stability and formation of 
lipid shelves.
In physical terms, the more dense islands of sphyngolipid-, cholesterol- and 
saturated-rich domains, representing lipid rafts, exist in a liquid-ordered state 
(‘lo’ phase). It is widely accepted that rafts exist in nerve cell membranes in the 
liquid-ordered phase display limited lateral and rotational mobility in the bilayer. 
Cholesterol molecules intercalate filling gaps in sphingolipid packing, and increases 
the rigidity and molecular density of bilayers in lipid rafts due to its ability to 
tightly pack with saturated lipids when the lo phase is formed [30, 31]. The sur-
rounding phospholipid bilayer enriched in unsaturated acyl chains exist in a 
state termed ‘liquid-crystalline’ or ‘liquid-disordered, ld’, and represent non-raft 
domains, in which the lipid acyl chains are fluid and disordered, exhibit much 
higher intermolecular mobility. The degree of disorder within this ld phase in nerve 
cells is considerable, as they contain the largest amount of polyunsaturated fatty 
acids (n-3 ad n-6 series) in the whole organism. Phospholipid-rich sphingolipid-
poor liquid-crystalline domains (non-rafts) and sphingolipid- and cholesterol-rich 
liquid-ordered phase domains (rafts) exist in dynamic equilibrium in biological 
membranes [31, 32].
The fact that lipid rafts are in an ordered lo phase provides them an extremely 
useful property for technical purposes: they are resistant to solubilization in the 
cold by nonionic detergents (such as Triton X-100) and therefore can be isolated by 
differential ultracentrifugation as ‘detergent-resistant membranes’ or DRM (refer-
ring to the physical structure isolated by detergent insolubility, while the term ‘raft’ 
refer to the microdomain in the intact membranes). This has allowed the identifica-
tion of proteins and lipids which display preferential (or exclusive) partitioning into 
rafts [32] (Figure 1C).
A number of proteins have been found associated to DRM and the list of candi-
dates is steadily growing [33]. The term ‘raftophilic’ has been coined to refer to the 
preferential location of these proteins in DRM or lipid rafts (Figure 1C). Recently, 
a database (RaftProt), containing more than 47,000 entries (V2.0, 2020 version) 
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of putative raftophilic proteins identified in mass spectrometry studies of isolated 
DRMs has been published [34]. Many of these proteins are not prototypical trans-
membrane proteins but display post-translational modifications aimed at favoring 
their targeting to lipid rafts (Figure 2). The first family of proteins described is 
GPI-anchored proteins. This family of proteins is anchored to the outer leaflet of the 
membrane through covalent attachment to a special glycolipid, glycosyl phospha-
tidylinositol (GPI) [35]. Amongst the GPI-anchored proteins involved in neuronal 
physiology, one of the best characterized is the cellular prion protein (PrPc) [36]. 
PrPc is constitutively expressed in neurons and preferentially localized in lipid rafts. 
PrPc is known to play different physiological roles in nerve cells, including regula-
tion of ion channels and neurotransmitter receptors at the pre- and postsynaptic 
levels [37] and has been linked to the pathogenesis of prion disease as mentioned 
before [36]. Prion disease is characterized by the conformational modification of 
normal PrPc into a misfolded and aggregated abnormal conformer, the pathogenic 
infectious form PrPsc, [38]. Current evidence indicates that conversion into PrPsc is 
entirely dependent on the lipid raft microenvironment [38].
Other raft-associated proteins are linked to saturated acyl chains through bio-
chemical processes grouped as lipidation [39] (Figure 2). Lipidation is particularly 
important for membrane binding of peripheral membrane proteins (though it may 
also occur in transmembrane proteins). Often these proteins are directly acylated in 
specific residues with two or more palmitate chains, or a palmitate and a myristate 
chain. These lipid modifications, named S-palmitoylation and N-myristoylation, 
are finely regulated and determine not only the fate of modified proteins to target 
lipid rafts, but also contribute to their stabilization within the domain and modulate 
protein interactions occurring within rafts. Such post-translational modifications 
are commonly found in Src family of tyrosine kinases (STKs) [40] and scaffold-
ing proteins [41]. Prenylation of proteins is also a lipidation mode for membrane 
association, consisting on a covalent attachment of an isoprenoid chain (either 
farnesyl- or geranyl-) to the C-terminus of proteins favoring their membrane 
association. This type of modification are common between members of the small 
G-proteins family, including Ras and Rab proteins involved in cellular signaling and 
oncogenicity [39, 42].
Common hallmark proteins of lipid rafts are caveolins and flotillins (Figure 2). 
These raft-resident proteins act as scaffolding structures within these microdo-
mains [43, 44]. It should be mention that caveolin family was first known for its 
participation in the formation of caveolae, membrane invaginations involved in 
endocytosis and signaling commonly observed in non-neuronal cell types such 
endothelial or epithelial cells [45]. Soon after, caveolin-1 was shown to display 
high affinity for rafts, and to be consistently extracted in DRMs. Though these 
two families of scaffold proteins are not transmembrane proteins, they undergo 
palmitoylation, allowing their anchoring to the cytoplasmic leaftet of the bilayer, 
and have the intrinsic capacity to form lipid shells around themselves [43]. Most 
evidence suggests that the lipid-modified nature of these scaffolds proteins 
integrated in lipid rafts serve not only to aid targeting them to these domains but 
also to stabilize rafts themselves. In line with this, caveolin-1 tends to form high-
molecular-weight oligomers which associate with each other in the plane of the 
membrane [44]. Further, numerous studies have concluded that these scaffold 
proteins help to compartmentalize specific signaling molecules within lipid rafts, 
and to modulate the specificity of protein interactions, with the final prospect of 
rapidly and selectively modulating cell signaling events [28, 46]. In this sense, the 
presence of caveolin-binding motifs in many raft proteins allow them to bind to the 
scaffolding domain of caveolin, which serve as a molecular filter to gather related 
signaling proteins close to each other, and to support additional protein–protein 
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interactions [47]. In the case of flotillins, an evolutionarily conserved domain 
named “prohibitin homology domain” (PHB) determines the affinity for flotillins 
and the raftophilic nature of proteins carrying it [48]. These properties are crucial 
for the formation of dynamic multimolecular platforms termed signalosomes, with 
complex functions in normal and pathological nerve cells.
3. Lipid rafts in neuronal cell signaling
Current evidence demonstrate that neuronal lipid rafts serve as docking 
platforms that bring together a number of specific proteins which determine the 
specificity of neuronal functioning and communication. They include different 
families of proteins with functions as receptors, ion channels, transporters, mem-
brane-bound enzymes, signaling proteins, interacting proteins, molecular adap-
tors, amongst others. They all share a special ability to interact with surrounding 
lipids mainly through lipid modifications, such lipidation with lipophilic anchors 
(S-palmitoylation and N-myristoylation, prenylation, GPI-anchoring) or to cho-
lesterol itself or by specific domains in their secondary structure to facilitate their 
integration in lipid rafts, such cholesterol recognition amino acid consensus (CRAC 
motifs) [49] and phospholipid binding sites [50]. In general, the integration of a 
protein in the raft membrane initiates interaction with surrounding proteins within 
multimolecular complexes or signalosomes which are dynamically recruited to lipid 
rafts in response to specific stimuli. They are believed to rearrange into large, stable 
membrane rafts, and to associate to downstream signaling molecules when bound 
to cognate ligands, activating signalosomes, and eventually triggering specific 
biochemical events involved in the many facets of neuronal physiology [2–4, 32].
One of the best studied multimolecular complexes in neurons is membrane 
rafts in postsynaptic neurons, which along with PSDs (postsynaptic densities), are 
considered major sites of synaptic signaling [3, 51]. In depth proteomics analyses 
performed by [52] in PSD have allowed identification of a number of proteins 
(>150) in PSD-included lipid rafts which are exclusive for postsynaptic membrane 
rafts, and not shared by non-raft portions of PSD. Most of these proteins could 
be classified as typical raft proteins (i.e. flotillin-1 and 2, PrPc), cell adhesion 
molecules (i.e. contactin, cadherin), ion channels (i.e. voltage-dependent calcium 
channels, inwardly rectifying potassium channels, NGF-gated Ca2+ channels), 
transporters (i.e. facilitated glucose transporter, high affinity glutamate transporter, 
GABA transporter protein, H+-ATPase), kinases/phosphodiesterases (i.e. Ca2+/
calmodulin-dependent protein kinase II, phosphodiesterase 2A, cGMP-stimulated) 
and G-proteins/small G-proteins (i.e. heterotrimeric G-protein subunits, members 
of RAS oncogene family) [52, 53].
The scenario emerges that, at least in PSD, the high protein density in raft 
membranes creates a crowded environment in which lipid–lipid packing is affected 
by proteins, probably with a stronger effect inside the more ordered raft-like 
domains [54]. Even more, it could be envisaged that this dense packing would limit 
intradomain mobility and thereby affecting protein interactions and conforma-
tional changes. To this author, this is one of the principal reasons to explain the 
evolutionary selection of significant amounts of highly unsaturated long chain fatty 
acids (LCPUFA) in nerve cells lipid rafts, which we have consistently found in brain 
raft preparations from different origins [55, 56]. Indeed, brain tissue contains the 
largest amount of LCPUFA in the whole body, well above the adipose tissue, and 
more importantly, they are contained exclusively in cell membranes. Most frequent 
LCPUFA in nerve cells are docosahexaenoic acid (DHA, 22:6n-3) and arachidonic 
acid (AA, 20:4n-6), whose acyl chains contain 6 and 4 double bonds, respectively. 
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The amounts of these fatty acids in neuronal membranes differ between rafts 
and non-rafts domains, the later containing 3-4 times more LCPUFA than raft 
membranes [57, 58]. Even so, the degree of polyunsaturation of lipid rafts provides 
a sufficient degree of fluidity in the lo domain of lipid rafts, and a physical mecha-
nism to ensure lipid and protein movements, such lateral and rotational diffusional 
rates as well as conformational displacements, required for proper intermolecular 
interactions [59, 60]. The regular bends introduced by the double bonds in the 
acyl chain of DHA and AA limit the stiffness of the packed bilayer and confer raft 
proteins a degree of motion freedom enough to accomplish molecular interactions. 
It is worth mentioning that, on a molar base, the contribution of unsaturation 
to bilayer fluidity is much higher for LCPUFA than for monounsaturated fatty 
acids, the most important in brain membranes being oleic acid (OA, 18:1n-9). In 
neural lipid rafts, this effect of LCPUFA on difussional rates is amplified by the 
unfavorable and repulsive interactions between the high cholesterol levels and 
polyunsaturated phospholipids [54, 61]. Overall, the lipid scenario in nerve cell 
lipid rafts renders them less ordered than in similar domains from non-neural cells. 
Importantly, destabilization of this physicochemical property of neural lipid rafts 
underlie dramatic consequences in lipid raft functioning in Alzheimer’s disease, as 
we will discuss in next sections.
Perhaps largest evidence demonstrating the significance of lipid rafts in nerve 
cell function is neurotrophic factor signaling. Most receptors for neurotrophic 
factors are receptor tyrosine kinases (RTKs) residing (or recruited to) lipid rafts 
which are activated upon binding to the specific trophic factor and undergo 
activation autophosphorylation of specific tyrosine residues. Activated RTKs are 
docking proteins for multimolecular complexes or signalosomes that activate 
downstream intracellular signaling cascades through molecular adaptors which 
are also raftphilic. Final effectors of RTK signaling are keys for regulation synaptic 
 transmission, differentiation, axon guidance and cell adhesion [2, 62].
Receptor tyrosine kinases observed to reside in lipid rafts include tropomyosin-
related kinase A (TrkA) receptor and the low-affinity p75 neurotrophin receptor 
(p75NTR), which are receptors for Nerve Growth Factor (NGF) [63], IGF-1R 
(insulin growth factor-1 receptor) [64], EGFR (epidermal growth factor receptor) 
[65] or PDGFR (platelet-derived growth factor receptor) [66, 67], amongst others. 
Alternatively, RTKs that are not lipid rafts resident proteins, may translocate to 
rafts after activation, as it was initially demonstrated for glial-derived neurotrophic 
factor (GDNF)-mediated activation of the Ret RTK [2].
The Src family of protein tyrosine kinases (STKs) is composed by integral raft 
proteins widely expressed in the CNS and are particularly abundant in neurons. 
Src is the best studied STK, is ubiquitous but in nerve cells are expressed as differ-
ent isoforms in a neuron-specific mode. It has been reported that at least five SFK 
members, Src, Fyn, Lck, Yes and Lyn are ubiquitously expressed in the central 
nervous system (CNS). These molecular transducers interact with, and participate 
in signaling from RTKs through different downstream pathways (MAPK, PI3-K, 
PKB/Akt, FAK) required to elicit neurotrophic responses such neurite outgrowth, 
myelination, axon guidance, proliferation and differentiation during CNS develop-
ment [68–70]. In the developed CNS, STKs are involved in a number of additional 
functions, as diverse as regulation of neuronal apoptosis [71] or upregulation of 
ionotropic NMDAR (N-methyl-D-aspartate receptor) and other ion channels [72]. 
It is worth recalling that NMDARs are the main type of glutamate receptors that 
mediate fast excitatory transmission in central synapses, and are often located 
in lipid rafts. By modulating NMDARs, Src gates NMDAR-dependent synaptic 
potentiation and plasticity, critical for processes underlying learning and memory 
[72]. Aberrantly regulated STKs antagonize cell survival signaling pathways and 
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induce neuronal apoptosis. Excitotoxicity is a major cause of neuronal death in 
acute and chronic neurodegenerative diseases [73]. This phenomenon is initiated by 
overstimulation of glutamate receptors, leading to sustained intracellular calcium 
overload and the constitutive activation of calpains, a family of calcium-activated 
proteases [74]. Calpain-mediated truncation of Src triggers excitotoxic neuronal 
death by inactivation of downstream Akt survival signaling [75]. Further to their 
effects on Src, overactivated calpains also affect different kinases GSK3β and CDK5, 
which lead to hyperphosphorylation of tau protein [76], one neuropathological 
hallmark in Alzheimer’s disease, as we will show in next sections.
Non-conventional trophic/survival factors involved in neuroprotection have 
been reported in lipid rafts, one of this factors being estrogen receptors (ER) [77]. 
The presence of ER in the plasma membrane of nerve cells was not without contro-
versy because classical ERs (alpha and beta) are cytosolic proteins with no affinity 
for hydrophobic domains. However, it is now clear that a subpopulation of ERα 
is associated to the nerve cell membranes, and that they are responsible for non-
conventional effects of estrogens [78]. The accepted model indicates that targeting 
of ERs to membranes may be achieved by palmitoylation [79] and this explains 
the presence of ERα in lipid rafts [80]. Recent evidence shows that activation of 
membrane ER trigger survival signaling pathways involving transient activation 
of Raf-1/MEK/MAPK cascade [78] in a synergistic crosstalk with c-Src-receptor 
tyrosine kinase pathways [81] are neuroprotective and prevent neuronal death in 
models of Alzheimer’s disease [77, 78, 80].
Coherent interactions of functionally related proteins have been demonstrated in 
lipid rafts. The new dimension of complex physiological processes but biochemically 
related at a nanoscale level have led to the concept of signalosomes. A pioneering 
study by Chadwick and collaborators (2010) in brain cortical lipid rafts form a trans-
genic model of Alzheimer’s disease (3xTgAD mice) have shown that synaptic and 
signaling networks are organized into multiprotein complexes in lipid rafts, enabling 
coherent clustering of synergistic signaling proteins. Remarkably, significant 
alterations in numerous receptor/cell signaling protein associations were detected 
in the transgenic AD model [82]. These finding are quite relevant for the disease in 
humans, as synaptic dysfunction is one of the hallmarks of AD [3, 83, 84].
Similar signaling platforms operate in neuronal mechanisms involved in neuro-
protection against different toxic insults (including amyloid β). The signalosome 
described by our group in lipid rafts from human frontal cortex is particularly rel-
evant because its implications in neuronal survival and death. Our recent research 
indicates that lipid rafts are the site of formation of a complex set of interactions 
between survival/growth factors ERα (described above) and IGF-1R, scaffold-
ing Cav-1, NMDA receptor regulator PrPc (physiological role), and ion channels 
pl-VDAC (a plasmalemmal form of mitochondrial voltage gated anion channel 
VDAC1) and NMDAR. This ER-signalosome likely contains signal transducers such 
heterotrimeric G-protein and STK such Raf-1 involved in neuronal ERα signaling. 
Unlike in other signalosomes, in this case, proapoptotic protein (pl-VDAC) share 
a common cluster with survival factors [80, 85, 86]. pl-VDAC has been found as 
a resident protein of lipid rafts in hippocampal and septal cell lines, mouse hip-
pocampus and frontal cortex, and human cognitive areas, such as frontal cortex, 
septum and hippocampus [85, 86], suggesting that location of VDAC in neuronal 
rafts may be a general phenomenon. Although the exact role of this mitochondrial 
channel in cell membrane lipid rafts is still under debate, pl-VDAC has been claimed 
to participate in the extrinsic apoptotic pathway [87]. The presence of pl-VDAC 
(and perhaps NMDAR) in lipid raft ER-signalosome suggest that they might be a 
critical site involved in neuronal fate decision, a fact that might be relevant in AD 
neuropathology, as discussed in the next sections.
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The preferential location of different neurotransmitter receptors (NTR) and ion 
channels has been demonstrated steadily since the discovery of lipid rafts in nerve 
cells, and the number of candidates keeps growing and far from being definitive. 
An excellent review and overview of neurotransmitter receptors and transporters 
associated with lipid rafts in neurons and glial cells can be found in [3]. The range of 
NTR involved is all-encompassing and include ionotropic receptors, such AMPA-R 
(α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor), NMDA-R, 
GABAAR (γ-aminobutyric acid receptors) or nAChR (nicotinic acetylcholine recep-
tors), metabotropic receptors such mAChR (muscarinic acetylcholine receptors), 
5-HT-R (serotonin receptors) or mGluR (glutamate receptors), neurotransmitter 
transporters such EAAT (excitatory amino acid transporters), and many GPCR and 
G-proteins such Gα and Gβγ (See [3] and references therein).
Often, these proteins are not stable raft-resident proteins but behave dynami-
cally and may traffic into or out lipid rafts, undergoing stimuli-induced integration 
in lipid rafts, which allow them interacting with transducers and even effector 
proteins (i.e. GPCR, G-protein-coupled receptors) or multimer formation (i.e. 
ionotropic receptors) to trigger either increase or dampen signaling responses. 
Lipid rafts also participate in the formation of neurotransmitter receptor clusters 
(i.e. NMDAR and GABAAR in postsynaptic neurons) influencing synaptic func-
tion, and are sites for endocytosis and trafficking of NTR. During neurotransmitter 
signaling, many GPCRs undergo agonist-induced endocytosis, leading to recep-
tor recycling, sequestration and downregulation through clathrin-independent 
 mechanisms [88, 89].
A number of neurotransmitter-independent ion channels have been found 
either as proper residents or transiently associated to lipid rafts. These proteins 
are generally downstream effectors of neuronal signaling and include the large 
family of voltage-dependent (Kv) potassium channels, Ca2+-activated K+ channels, 
different subunits of voltage-dependent sodium (NaV) and calcium channels (CaV), 
VDAC and ClC families of voltage-gated chloride channels, G-protein-gated or 
cyclic nucleotide-gated (CNG) ion channels, transient receptor potential (TRP) 
cation channels, and water (AQP) channels [3, 52, 85, 90–92].
Structurally, ion channels are diverse in their architecture and topology, but 
generally contain several transmembrane domains, which allow integration within 
lipid rafts mainly through hydrophobic lipid-protein interactions with acyl chains 
of surrounding lipids within the lipid bilayers, and also with phospholipid head 
groups at the level of intra- and extracellular aqueous interfaces, being these lipid 
interactions absolute requirements for proper channel gating.
Further, members of all major ion channel families have been demonstrated 
to be regulated by membrane cholesterol and to partition into cholesterol-rich 
membrane domains [93]. Stability of channel proteins in lipid rafts is ensured by 
hydrophobic interactions of transmembrane domains with cholesterol within the 
core of the bilayer. Cholesterol itself not only provide channel compartmentaliza-
tion but also alters the kinetic properties and current–voltage dependence of many 
voltage-dependent channels, particularly in voltage-gated Na+ and K+ channels 
[93]. Targeting of ion channels is isoform-specific, as demonstrated for Kv channels 
Kv2.1, Kv1.4 and Kv1.3, which are present in distinct membrane compartments in 
hippocampal and cortical cells [90, 94]. Apparently, membrane domain choles-
terol levels differentially modulate the trafficking and localization of Kv channels 
[90, 95]. Overall, ion channels targeting to lipid rafts channel induces not only 
clustering to other raftphilic partners, but also modulation of ion channel gating by 
virtue of microenvironmental cholesterol.
Finally, lipid rafts are associated with cytoskeleton [96]. Interactions with 
cytoskeletal components (actin, tubulin, vinculin, filamin, and tau) contribute 
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to the regulation of lipid rafts assembly and clustering. The accepted view is that 
this depends on raft lipids, raft scaffold proteins and submembrane actin network 
[96, 97]. It has been proposed an intuitive model (“picket-fence”) whereby actin 
filaments anchored to cytofacial leaflet of lipid rafts regulate lateral diffusion of 
adjacent membrane lipids and proteins [97]. Anchoring of actin filaments with 
raftphilic proteins have been proposed to allow the transient clustering and coalesc-
ing of small rafts to form larger homo - and hetero -GPI-anchored oligomeric rafts, 
through raft-based lipid interactions that generate functional raft domains [98]. This 
spatiotemporal microdomain clustering depends upon cholesterol, sphingolipids, 
phosphoinositol lipids and the cortical actin meshwork, where actin filaments 
cross-linked by myosin motors promote energy-dependent lateral movements of 
GPI-anchored proteins [98]. Besides actin, tubulin is also associated to lipid rafts and 
co-precipitates with caveolin-1 in brain extracts. In fact some authors have suggested 
that tubulin itself might behave as a scaffolding protein in lipid rafts [3]. Recent 
studies have shown that lipid rafts lipids are important elements in the interaction 
membrane-cytoskeleton. Thus, It has been shown that phosphoinositide lipids such 
as PtdIns(4,5)P2 and PtdIns(3,4)P2, which accumulate in the inner leaflet of lipid 
rafts, bind actin and direct actin assembly into filaments, and that PtdIns (4,5)P2 
serves as a tubulin anchor on the plasma membrane [3, 96]. It is known that microtu-
bule dynamics participate in raft-associated neurotransmitter signaling [3]. Certain 
G proteins have been shown to promote the GTPase activity of tubulin and to affect 
microtubule arrangement. The association between tubulin and heterotrimeric G 
proteins has been demonstrated to potentiate adrenergic and cholinergic signaling 
neurotransmitters by directly activating their respective G proteins [3]. Further, 
cytoskeletal dynamics and its interaction with lipid rafts are demonstrated to be 
directly involved in processes such neuronal growth, axonal/dendritic guidance, 
axonal regeneration and dendritic spine formation in hippocampal neurons [3, 96].
4. Lipid rafts in established AD
4.1 AD neuropathology: linking in lipid rafts disturbances
Alzheimer’s disease is the most common neurodegenerative disease, and has 
reached pandemic proportions in developed countries. AD is characterized by 
progressive memory loss, cognitive deficits and subsequent gradual but relent-
less dementia. In the majority of cases AD occurs late in life and without a known 
cause (referred to as “sporadic” or “late-onset” Alzheimer’s disease, LOAD). Brains 
of individuals with AD exhibit massive loss of synapses and neurons, as well as 
extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs). 
The most severe neuropathological changes occur in the hippocampus, followed by 
the association cortices and subcortical structures [99, 100].
The major proteinaceous component of SPs is a 40–42 amino acid polypep-
tide amyloid-β derived by proteolytic cleavage from the transmembrane protein 
APP. According to the amyloid cascade hypothesis (first proposed by Hardy and 
Higgins, 1992) [101], in the amyloidogenic pathway, the β-secretase activity of 
BACE1 (β-site APP cleavage enzyme 1), generates the amino terminus of Aβ [102] 
while γ-secretase complex (made up of four proteins: presenilin, APH-1, PEN2 and 
nicastrin) [103] cleavage at the carboxy-terminus and determines its length (Aβ40 
and Aβ42). Aβ40 is the most common species and Aβ42 the more fibrillogenic and 
prone to aggregates in SPs [104]. As discussed below, lipid rafts are the key mem-
brane domain for this sequential cleavage of APP. Conversely, in the non-amyloido-
genic pathway, the zinc metalloproteinase ADAM10 named α-secretase, cleaves APP 
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within the Aβ domain [105, 106] and thus precludes Aβ formation. Of note, action 
of α-secretase occurs predominantly in non-raft domains [105, 106]. A reciprocal 
relationship exists between non-amyloidogenic and amyloidogenic APP processing 
such that impaired ADAM10-mediated proteolysis of APP serves to enhance amy-
loidogenic processing thereby elevating levels of Aβ peptides in AD-afflicted brains 
[105]. These assertions are extremely important for AD onset and progression, 
since it suggests a dynamic intramembrane and interdomain competition between 
proteolitic activities of α- and β- secretases on APP, which largely determine the bal-
ance between amyloidogenic and non-amyloidogenic patwways. Further, increasing 
evidence indicates that ADAM10 may also affect AD pathology through potential 
mechanisms including reducing tau pathology, maintaining normal synaptic func-
tions, and promoting homeostasis of neuronal networks [106].
Fibrillation of amyloid β peptides is a critical and complex process largely 
responsible for amyloid toxicity [107]. The available evidence favors a model in 
which the conversion of the normally soluble Aβ peptide into insoluble oligomeric, 
protofibrillar, and fibrillar toxic forms [104, 107].
NFTs are also a pathological hallmark of AD, though not exclusive. NFT are 
also present in other taupathies such frontotemporal dementia [108]. NFTs contain 
abnormally hyperphosphorylated forms of the microtubule-associated protein tau, 
which causes detachment of tau from microtubules and the formation of insoluble 
tau aggregates. This leads to the occurrence of paired helical filaments and NFTs 
present in cell bodies and apical dendrites as neurofibrillary tangles (NFTs), but 
also in distal dendrites as neuropil threads, or in abnormal neurites associated 
to SPs [109].
A number of studies demonstrate that AD-associated cognitive dysfunction is 
strongly correlated with the accumulation of amyloid-β and hyperphosphorylated 
tau, however, the precise relationship(s) between neurological and biochemical hall-
marks of AD remains incompletely understood, particularly in Sporadic Alzheimer’s 
disease. Likewise, potential causes for AD remain unknown, except for the familial 
form of the disease (familial AD, FAD), in which several genetic mutations on pro-
teins involved in amyloid β production have been well-identified [84, 110]. In FAD, 
which accounts for less than 1% of the total AD cases, rare autosomal dominant 
mutations have been identified in three genes, namely APP, PSEN1 and PSEN2, the 
latter two being the most common mutations found in FAD [84, 110].
Regarding the relationship between alterations amyloid-β and tau in 
AD-afflicted brains, current models suggest that amyloid oligomerization and 
aggregation drives tau hyperphosphorylation and fibrillation. By itself this modi-
fied form of tau stimulates cell dysfunction and neurodegeneration in AD both 
downstream and independently of Aβ [84, 111].
4.2 Lipid rafts and amyloid processing
Numerous studies have shown that proteins involved in amyloidogenic process-
ing pathway APP, BACE1 and the γ-secretase complex are transmembrane proteins 
associated to different extents to lipid rafts (see the excellent review by Hicks et al., 
2012) [6]. APP is localized in raft and non-raft fractions, but predominates outside 
rafts, while the β- and γ-secretases are mainly located in rafts. Noteworthy, APP and 
secretases exist in two pools, raft and non-raft, but their relative residence fraction 
vary depending on cellular signals and physicochemical microenvironmental factors 
(i.e. lipid composition of bilayer, see below). Conversely, the α-secretase involved in 
non-amyloidogenic pathway is membrane- but not raft-associated [106].
Regulation of APP raft localization involves interaction between the C-terminus 
of APP and flotillin-1 [112]. Further, another factor promoting raft localization of 
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APP is cholesterol. APP specifically binds cholesterol though a direct interaction 
with the C-terminal domain C99 (also known as β-C-terminal fragment, β-CTF) 
[113]. Apparently, binding of cholesterol to C99 would favor the amyloidogenic 
pathway in cells by promoting localization of C99 in lipid rafts [113].
Regarding secretases, raft localization of β-secretase and interaction with raft-
resident lipids is mediated by palmitoylation of BACE-1 [114]. It has been reported 
that when BACE-1 is targeted to lipid rafts via GPI-anchoring, upregulation of amy-
loidogenic APP processing occurs and production of Aβ is increased [115]. Subunits 
of the γ-secretase complex are enriched in lipid rafts by means of S-palmitoylation 
of nicastrin and Aph-1 [116, 117] but, interestingly, does not directly modulate 
γ-secretase processing of APP [117]. Further, the lipid raft scaffolding protein 
caveolin-1 influences the γ-secretase spatial distribution favoring its partitioning to 
lipid rafts but also enhances its secretase activity [118].
Another important lipid-raft associated protein which was shown to play an 
important role in APP processing is PrPc. Indeed, PrPc regulates APP processing by 
inhibiting β-secretase activity in the cell surface, and this effect requires the local-
ization of PrPc to lipid rafts [6, 119]. This led to the hypothesis that PrPc might be a 
key protective protein against AD, and that PrPc downregulation might impede the 
negative control of BACE1 activity and accumulation of Aβ peptide. However, no 
decrease of PrPc content has been reported in AD brains, therefore it is suggested 
that decreased ability of PrPc to control BACE1 might be consequence of age- and 
disease-dependent disruption of lipid rafts, at least in the case of sporadic AD [6].
The relationship of amyloid peptides and membrane components is often 
reciprocal. Several examples illustrate this bidirectional relationship. First, PrPc has 
been shown to be a receptor for Aβ oligomers (even at nanomolar concentrations). 
Binding of Aβ oligomers to PrPc results in the blockage of hippocampal LTP and 
reduction of PrP affinity for the NMDAR (through a complex allosteric modulation 
of its glycine binding site). Once out of the control by PrP, this results in steady-
state NMDAR currents and excitotoxicity [6, 120]. Together with BACE1 regulation 
by PrPc explained above, this provides an integrated toxicity mechanism explaining 
the interplay between BACE1, PrPc, NMDAR, Aβ species and hippocampal LTP, in 
the hippocampal degeneration and functional decline in AD.
A second example is brain cholesterol. Within nerve cells, the biggest reser-
voirs of cholesterol are found at the plasma membrane, myelin sheaths and in the 
endocytic recycling membranes. The majority of brain cholesterol is derived from 
de novo biosynthesis, rather than from plasma LDL [121]. Cholesterol can directly 
modulate amyloidogenic secretase activities leading to altered amyloid-β genera-
tion [10, 122–124]. Collectively, these data indicates that elevated cholesterol levels 
promote the co-clustering of APP and BACE1 in lipid raft domains, as well as their 
rapid endocytosis, and increases their activities. Conversely, experimental reduc-
tion of membrane cholesterol levels decreases the association of BACE1 with lipid 
rafts and reduces the activity of both BACE1 and γ-secretase, leading to additive 
reduction of amyloid-β production.
Cholesterol levels in the brain are regulated through a series of steps in a cross-
talk between astrocytes and neurons (see excellent reviews by [125–127]). These 
involve HMG-CoA reductase (HMG-CoA, the rate-limiting enzyme responsible for 
cholesterol synthesis in neurons and glial cells), APOE-containing HDL-like parti-
cles released from astrocytes (which mediates the uptake of lipoprotein particles via 
LRP), LDL receptor-related protein (LRP, which serves as a neuronal receptor for 
astrocyte-produced APOE-containing lipid particles), ATP-binding cassette sub-
family A member 1 (ABCA1, mediating cholesterol efflux from neurons has been 
also shown to modulate Aβ levels in neurons), and acyl CoA:cholesterol acyltrans-
ferase 1 (ACAT1, which converts free cholesterol into cholesteryl esters), amongst 
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other proteins. Excess free cholesterol in neurons is either converted to cholesteryl 
esters by ACAT1 or exported through ABCA1. Several lines of evidence indicate that 
cholesterol efflux, synthesis or esterification controls amyloid-β generation. Thus, 
stimulation of HMG-CoA or ACAT1 has been demonstrated to increase Aβ levels 
though mechanisms still poorly understood. Further, in vivo studies have shown 
that deletion of ABCA1 gene decreases the levels of APOE, a finding that correlates 
with greater amyloid-β deposits. Moreover, increased intracellular cholesterol (and 
perhaps cholesterol esters) has a considerable impact on membrane domain bio-
genesis and lipid raft formation, eventually leading to stimulation of amyloidogenic 
APP processing [128–130].
4.3 Untangling the conundrum of late-onset AD origin
Despite intense scientific research in the areas of genetics, molecular and cell 
biology, and neuroscientists throughout the world, causative factors for nerve 
cells destruction in LOAD are far from conclusive and have not been definitively 
established. Amongst factors evidencing solid links with neuronal loss and develop-
ment of sporadic Alzheimer’s disease are genetic polymorphisms, such ApoE4 [102, 
103], neuroinflammation [104–106, 131], oxidative stress [107–110], neurolipid 
deregulation [111–114, 131], environmental factors, such chronic exposure to 
neurotoxic metals, pesticides or nanoparticles [115–117], dietary habits [118–121], 
and xenoendocrine and hormonal changes such menopause [1, 122, 123]. However, 
the only factor that is unequivocally associated to the onset of AD is aging. Aging is 
an extremely complex biological process affecting whole organism. Cerebral aging 
is acknowledged to involve multiple factors which converge to reduce cognitive func-
tions such as mental speed, executive function, episodic memory, working memory, 
short-term recollection, spatial memory and capability to process new information, 
amongst other deficits [92, 124, 125]. These cognitive deficits are recognized to be 
secondary to losses in synaptic contacts, reduced neuroplasticity, dendritic branch-
ing, changes in neuronal and/or astrocyte physiology and crosstalk [126], and is 
accompanied by reductions in the volume of the hippocampus and pre-frontal, pari-
etal, temporal and entorhinal cortical parenchyma [92]. Not surprisingly, brain areas 
which are more neuroplastic throughout life, such hippocampus and entorhinal 
cortex are most vulnerable to age and more prone to undergo pathological neurode-
generation [126]. Indeed, neurons that are particularly vulnerable in AD include the 
pyramidal layers of the hippocampus, those in layer II of the entorhinal cortex, and 
from certain areas of the neocortex (frontal, parietal and temporal cortices) [92]. 
Although most vulnerable neurons use glutamate as neurotransmitter (the most 
common in the brain), there is also significant loss cholinergic and noradrenergic 
neurotransmission in subcortical neurons in the basal forebrain [127]. In particular, 
the dysfunction of cholinergic neurons has received much attention (as per involved 
in obvious deficits in attention and memory in AD) and has been the stem for the 
“cholinergic therapy” in AD [127] Current knowledge support the notion that much 
of the cognitive dysfunction in AD is not due to loss of neurons containing a par-
ticular neurotransmitter, but to disruption of the network connections between key 
brain regions within the limbic system and specific areas of the neocortex [79].
My current view, shared with most neurologists and molecular and cellular neu-
robiologists, is that LOAD onset is determined by the slow but steady deleterious 
contribution of a combinatorial concert of factors referred above, superimposed to, 
and facilitated by both genetic predisposition and the exhaustion effect of lifestyle 
and aging. For instance, it is known that the apolipoprotein E allele e4 (APOEε4) 
expressed in the brain is a genetic risk factor for LOAD, whereas the e2 allele is 
protective. One copy of APOEe4 increases the risk for AD by ~3-fold and two copies 
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by ~12-fold (http://www.alzgene.org), but its effect is magnified by aging, with a 
decrease in age at onset by ~5 years/e4 allele, in both sporadic and familial forms 
of AD [84, 132–134]. In line with this, the Society for Women’s Health Research 
Interdisciplinary Network on AD, comprised of an expert panel of scientists and 
clinicians, has reviewed ongoing and published research related to sex and gender 
differences in AD, and defined the concert Age-APOE-Gender a triad of high risk 
for AD [133].
4.4 Lipid rafts: beyond and before amyloid possessing
The involvement of lipid rafts in AD extends well beyond facilitating amy-
loidogenic processing of APP or tau hyperphosphorylation. As described above, 
numerous neurotransmitter receptors, neurotrophic factors receptors and down-
stream signaling proteins, signalosomes, membrane trafficking components, ion 
channels and pathway effectors have been demonstrated to be differentially altered 
in Alzheimer’s disease. Indeed, the number of cellular and molecular biological 
processes known to be presumably affected in AD is enormous. It is conceivable 
that not all these evidences occur in real degenerating human brains, as most 
observations have been obtained under artificial in vitro conditions, or in vivo using 
cellular and animal models, often overexpressing human proteins not normally 
expressed in experimental animals. These same arguments may also explain why 
contradictory results or fundamental controversies from different research groups 
are found in the literature. Furthermore, very relevant information from studies 
aimed at disentangling the pathological mechanisms for AD has been obtained 
from transgenic mice models expressing human components of the amyloidogenic 
pathway from well-established mutations in familial Alzheimer’s disease. Thus, 
even if overexpressing transgenic models may render a disease scenario to closely 
resemble human amyloid and/or tau pathology, results are not necessarily translat-
able to the most common form of AD, i.e. LOAD. One plausible hypothesis which 
may assemble much information on the different mechanisms reported as altered 
in Alzheimer’s disease is that they may belong to a programme of sequential set of 
events triggered at the onset of the disease, in some kind of self-destructive parallel 
domino effects, which are exacerbated during the progression of the disease.
In this sense, plentiful and compelling evidence point to lipid rafts alterations as 
a common underlying factor related to AD neurodegeneration, even at very early 
stages of the disease. Moreover, it is now clear that these structures undergo aging-
associated modifications in brain areas even in subjects without signs of the disease. 
Overall, this suggests that it might be disentangling of lipid rafts a very early event 
in the transition from normal aging to developing this neurodegenerative disease.
It may be assumed that altered function of biochemical components integrated 
within lipid rafts may be secondary to destabilization of membrane structure of lipid 
raft, in particular with neurolipids. Indeed, a considerable number of studies demon-
strate that lipid biochemical and biophysical anomalies lead to abnormal functioning 
of lipid rafts [10, 135–137]. These issues are discussed in the next section.
4.5 Lipid abnormalities and lipid rafts dyshomeostasis in AD
In the seminal description of the degenerative disease in 1932 named after him, 
Alois Alzheimer highlighted the occurrence of ‘adipose inclusions’ or ‘lipoid granules’ 
as the third pathological hallmark of AD. This finding did not receive enough atten-
tion until recently. Subsequently, biochemical alterations of lipid composition have 
been reported in post-mortem brains from individuals with AD. Perhaps, the intimate 
link between lipid metabolism and AD was only boosted when the ε4 allele of the 
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APOE gene was identified as a strongest genetic risk factor for LOAD [130, 134, 138]. 
The involvement of lipids in AD is substantiated by a number of epidemiological 
studies which support a role for cholesterol and essential fatty acids in the pathogen-
esis of AD [138, 139]. It is now well established that most, if not all, classes of lipids 
are implicated in AD pathogenesis. (recently reviewed in Chew et al., 2020) [140].
A wealth of studies have consistently demonstrated the depletion of LCFUFA 
in brain tissue from postmortem AD brains, in particular for fatty acids of the n-3 
series, mainly docosahexaenoic acid (DHA) [131–144]. As mentioned before, brain 
is the organ containing the largest amount of DHA in the whole organism, and its 
depletion, underlie many alterations occurring during AD neurodegeneration. 
Indeed, DHA is a pleiotropic molecule. It is an essential component of nerve cells 
membranes associated to glycerophospholipids (mainly phosphatidylethanolamine, 
the most abundant phospholipid in nerve cells), and is largely determinant of 
physicochemical and biophysical properties of plasma membrane, such mem-
brane viscosity, lateral mobility, phase separation and microdomain segregation, 
conformational transitions and lipid-protein and protein–protein interactions 
[60, 145, 146]. Besides, DHA is an active modulator of neurogenesis, synaptogen-
esis and neurite outgrowth and in memory consolidation processes [147, 148], but 
also in the activation of survival signaling pathways against oxidative and proin-
flammatory insults, amyloid β production [149–151], and transcriptional activation 
of neuronal antioxidant systems [152, 153]. The importance of DHA for brain 
health is highlighted by the extensive epidemiological and experimental evidence 
linking its depletion with the development of neurodegenerative diseases [154, 155].
Another evidence linking LCPUFA and AD is that LCPFA, especially DHA and 
AA are highly susceptible for oxidative stress. The high metabolic rate and elevated 
oxygen consumption in brain tissue, together with the enrichment in redox transi-
tion metals, such iron and copper, favor the free radical-induced peroxidation of 
LCPUFA in the brain parenchyma [156–158], and generation of reactive lipo- / 
endo-peroxides such isoprostanes, neuroprotanes, malondialdehyde, acrolein, 
and reactive aldehydes such HHE and HNE [159, 160]. Further, unlike other 
forms of free radical injury, lipid peroxidation is self-propagating and generated 
lipoperoxides react with membrane LCPUFA to produce additional reactive lipo- 
endoperoxides, to provoke extensive brain tissue damage [157, 159]. Obviously, one 
main outcome of lipid peroxidation is the structural damage of membranes, which 
impairs nerve cell physiology and finally causes cell death.
Pioneering studies published by our group on lipid rafts from human frontal 
cortex have demonstrated altered lipid profiles in AD brains at advanced stages 
V-VI, compared to control brains [161]. Amongst other alterations, lipid rafts 
displayed abnormally low levels of n-3 long chain polyunsaturated fatty acids 
(LCPUFA) and unsaturation and peroxidability indexes. LCPUFA, mainly docosa-
hexaenoic acid (DHA; 22:6n-3), are particularly enriched in nerve cell phospholip-
ids, and their presence is an absolute requirement for neuronal membrane function 
[125, 146, 162]. The results in this study were relevant for two main reasons. First, 
lipid rafts showed that, even in non-AD subjects, neuronal lipid rafts contain 
significant amounts of polyunsaturations in the form of n-3 and n-6 acyl chains, 
which makes them less packed and ordered than supposed. These findings are not 
surprising as fatty acids have the capacity to influence plasma membrane organiza-
tion to facilitate intermolecular mobility (in a ´crowed´ protein environment such 
neuronal lipid rafts) by modulating membrane lipid composition, which affects 
functionality of lipid raft domains [145, 162]. Second, no changes in cholesterol 
were associated to lipid rafts in advanced stages of AD, which apparently contra-
dicted the observation that AD brains contained higher cholesterol levels than 
normal brains. However, these observations are reconcilable on the basis that bulk 
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brain cholesterol may increase by affecting non-raft domains, without change in 
lipid rafts. In this case, interaction of rigid sterol ring of cholesterol with membrane 
phospholipids renders non-raft domains less fluid than normal, a notion which is 
supported by biophysical observations [59, 60, 128].
Other important rafts-associated lipids are gangliosides. These glycerospingolip-
ids have been demonstrated to play a role as assembly- and aggregation-promoting 
factors [11, 17]. Aberrant levels and significant regional differences in the distribu-
tion of specific gangliosides have been observed in AD brains [10, 149]. Gangliosides 
are primary modulators of amyloid-β aggregation in AD, and it has been demon-
strated that binding of GM1 to amyloid-β trigger conformational changes towards 
more ordered structures with increased β-sheet content, which correlates with 
higher toxicity [17, 163, 164]. A number of studies have revealed that gangliosides 
accumulate in senile plaques favoring the conversion of Aβ to a neurotoxic oligomers, 
and accelerates the formation of amyloid fibrils [152, 165, 166], these effects being 
favored in the presence of the ApoE4 genotype [167]. It has been demonstrated that 
Aβ has a high affinity for GM1 containing membranes both in vitro and in vivo, and 
that the N-terminal region of Aβ promote interactions with GM1 clusters in lipid 
rafts through hydrogen bonding and electrostatic interactions [13, 168, 169]. Further, 
the participation of gangliosides in the development of Alzheimer’s disease is further 
strengthened by that fact that GM1 content in neuronal membranes, particularly in 
raft microdomains, increases with age [6, 152, 170]. In this sense, lipid raft GM1 acts 
as a ‘seed’ for amyloid-β aggregation [10, 151].
5. Lipid rafts alterations at early stages of AD
The presence of biochemical and physicochemical alterations in lipid rafts at 
early stages of AD has been recently reported [60, 171]. It is noticeable that lipid 
rafts are profoundly altered in the cortex of AD brains from the earliest stages 
namely AD I/II [172]. These changes affects the lipid matrix of lipid rafts well before 
the overt of clinical signs, and are retained as the disease progresses towards more 
advanced stages (stages III-IV) with little modifications. The most dramatic changes 
observed were the reductions in polyunsaturated arachidonic and docosahexaenoic 
acids, cholesterol, sphingomyelin, monounsaturated oleic acid, as well as increased 
levels of phosphatidylcholine and sterol esters [152]. Other reports have also shown 
elevated ceramide levels are and reduced sulfatides at the earliest clinically recogniz-
able stage of AD [173], likely involved in oxidative stress-induced neuronal death.
Paralleling these changes, lipid rafts from AD frontal cortex displayed abnor-
mally low unsaturation and peroxidability indexes, suggesting a high impact of lipid 
changes in physicochemical conditions of lipid rafts [60]. Lipid abnormalities in 
lipid rafts likely have a profound impact on membrane physicochemical properties, 
in particular to membrane order and microviscosity. We have shown that the reduc-
tion in n-3 polyunsaturated and the increase in saturated fatty acids, results in aug-
mented density of hydrophobic interactions between saturated hydrocarbon acyl 
chains of phospholipids and sphingolipids within the membrane plane [11, 54, 55]. 
The consequences are: laterally condensed and more packed membranes, and higher 
physical order and microviscosity, in spite of the reduction in cholesterol [55]. These 
findings are in agreement with the observations in lipid rafts from the neocortex 
of aged APP/PS1 mice reported recently [54], which display a similar increase in 
membrane microviscosity secondary to reduced n-3 LCPUFA and cholesterol levels, 
as determined by steady-state fluorescence anisotropy [59]. Moreover, we have dem-
onstrated that this transition towards more ordered membranes occurs during the 
initial stages of the pathology, and that it is correlated to the alterations observed in 
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the lipid profiles. A finding that is retained in intermediate stages of AD. The impact 
of these biophysical observations are likely relevant on the dynamics of amyloid 
aggregation. Indeed, it is known that interaction of Aβ with neural membranes is 
energetically more favorable in liquid-ordered membranes than in liquid-disordered 
counterparts and also that this association accelerate fibrillation [119, 158, 159, 174]. 
The relationship between liquid ordered-membranes and amyloid peptide associa-
tion is reciprocal. Indeed, studies performed in rat synaptic membranes and in 
human brain tissue have shown that different Aβ peptides reduce membrane fluidity 
by partitioning into the hydrophobic core of membranes [119, 158, 159] thus adding 
additional membrane order to lipid rafts.
One relevant consequence of altered physicochemical properties of lipid raft 
observed in human brain cortex is that these likely modify interactions between raft 
resident proteins, in particular those involved in the differential processing of APP 
(see below).
Surprisingly, anomalies in lipid rafts from early AD stages are clearly more severe 
than those found in late stages (V/VI) [147]. It can be speculated that the neuronal 
metabolic collapse and/or disruption of neuronal lipid homeostasis [175, 176] in late 
stages of the disease, overcome membrane biosynthetic mechanisms to maintain 
lipid raft structure. In turn, this would weaken the thermodynamically unfavorable 
boundaries and tension line between raft and non-raft domains, eventually leading 
to more homogeneous membranes [11, 22, 24, 28].
Noticeably, we observed that lipid rafts alterations specifically affect frontal and 
entorhinal cortices in the same subjects, two brain areas particularly affected in AD, 
while no substantial effects are observed in the cerebellum. Further, Noteworthy, 
alteration in neurolipid levels and biophysical properties occurs in the frontal cortex at 
stages I/II, a brain region that devoid of neuropathological hallmarks of AD (neurofi-
brillary tangles and senile plaques) at such early phase [156, 157]. Moreover, It is worth 
mentioning that, at least in the frontal cortex, no astroglial proliferation is present at 
stages I/II, and very little at stages III/IV and mainly associated to senile plaques [156, 
157]. Therefore, changes in lipid composition in lipid rafts in frontal cortex at early 
stages of AD pathology reflect modifications in the lipid composition of lipid rafts in 
neurons and cannot be explained by modifications in the neuron/astroglial ratio.
We extended our lipid analyses in the frontal cortex to entorhinal cortex and 
cerebellum, two other brain areas differentially affected in AD [109, 177, 178]. The 
results showed that alterations in lipid raft found in cortex are also present, and 
to a similar extent and disease-course, in entorhinal cortex [152]. It is known that 
enthorinal cortex is one of the first brain areas affected in AD, which exhibits the 
neuropathological traits at stages I/II [156, 157]. Overall, the fact that frontal cortex 
lipid rafts exhibit altered lipid profiles at stages AD I/II but not AD neuropatho-
logical hallmarks indicates that lipid raft destabilization develops well before the 
appearance of neurofibrillary tangles [100, 156, 157].
We have further explored the pathophysiological consequences of these altera-
tions in the amyloidogenic pathway during development and progression of AD. As 
expected, we have detected main components involved in amyloidogenic pathway, 
namely APP, β-secretase and γ-secretase in lipid rafts from the three brain areas, in 
control and AD brains. We have observed that while the stage of the disease does 
not alter the level of association between APP-BACE and APP-PSEN1 in cerebel-
lum, in the entorhinal and frontal cortices, the association between APP and BACE 
was considerably augmented when compared to the same areas in control lipid 
rafts. Conversely, physical association of APP and PSEN remained nearly constant 
between brain areas irrespective of disease stage. These findings are particularly 
relevant since β-cleavage of APP by BACE1 is the rate-limiting obligatory event, in 
the amyloidogenic pathway [6, 179, 180]. From a holistic perspective, the convergence 
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of APP and BACE to lipid rafts, allows a closer interaction between the two proteins 
facilitating β-cleavage of AβPP and eventually Aβ production [6, 179–182]. These 
observations point to the existence of homeostatic mechanisms precluding their 
unabated convergence under non-pathological conditions. In agreement, in a recent 
study in cultured hippocampal neurons, specific trafficking strategies that limit APP/
BACE-1 proximity in has been demonstrated under physiologic states [162], therefore 
limiting amyloidogenesis. However, in this later study, disturbing raft architecture by 
moderate (but not severe) reduction of cholesterol levels increase Aβ production by 
enhancing BACE1 and APP interaction [161, 162, 164]. Our results in human brain 
lipid rafts, agrees with this finding that moderate reduction in cholesterol facilitates 
convergence pathways that routes APP and BACE to lipid rafts. However, the most 
important factors in triggering this convergence are the reduction in LCPUFA and 
the increased proportions of saturates/n3 and phospholipids/cholesterol in lipid rafts 
from entorhinal and frontal cortices, which, as we have showed before, gives rise to 
more liquid-ordered microdomains, likely stabilizing the interaction of AβPP and 
BACE1. In this sense, lipids can build a physical boundary between domains, circum-
scribing the β-secretase-APP complex within the lipid raft domain, where the pool of 
γ-secretase resides, thus favoring the sequential amyloidogenic cleavage of APP [183].
On the other hand, plasmalogens, membrane glycerophospholipids abundant 
neuronal lipids, have also been associated to AD. Reduced levels of these brain-
specific lipids have been reported in AD brains [12, 184]. This is relevant for three 
main reasons: first plasmalogens (particularly plasmenyl-ethanolamine, PlsEtn) act 
as neuronal depots for essential LCPUFA in the brain and structural determinants 
of acyl chains packing and membrane order [23]; Second because the oxidative 
products of plasmalogens are unable to further propagate lipid peroxidation, and 
essential factor in triggering AD, thus plasmalogens may terminate lipid oxidation 
[185] and third, because they might have direct effect on the production of Aβ by 
inhibiting activity of γ-secretase [184].
Of particular interest is the fact that the normal aging brain undergoes a set 
of lipid alterations in lipid rafts collectively termed “lipid raft aging” [53, 94, 135, 
151, 152, 168]. Changes affect levels of sphingomyelin, sulfatides and cerebrosides, 
LCPUFA, plasmalogens, phosphatidylinositol, gangliosides, and total neutral lipids 
(mainly cholesterol and sterol esters). Further, relevant relationships between main 
fatty acids and/or lipid classes detected in younger subjects, either disappeared or 
they occurred in the opposite direction [157]. Noticeably, these changes are mostly 
subtle but follow the same trend observed in early stages of AD. “Lipid raft aging” 
also involves changes in unsaturation and peroxidability indexes though they are 
significantly less severe than those reported in AD cortex [56, 57], and do not cause 
significant biophysical alterations of raft membranes. The significant reduction 
in peroxidability indexes observed in early stages of AD (reflecting the important 
reduction of LCPUFA in both raft and non-raft domains), and especially dur-
ing lipid raft aging, is strongly indicative that oxidative stress and exhaustion of 
antioxidant systems are an essential part of AD neurodegeneration.
Interestingly, “lipid raft aging” exhibits clear gender differences and appear to 
be more pronounced in women, especially in older postmenopausal women [168], 
which strengthens a role for ovarian hormones in AD development. Indeed, accord-
ing to the Alzheimer’s Association [186] women have 2-fold greater lifetime risk of 
developing AD. Though still incompletely understood, it seems clear that menopausal 
transition and decline in estrogen adversely affect brain metabolism [187, 188].
Overall, the evidence accumulated point to a complex cocktail of factors, either 
endogenous and/or environmental, affecting lipid raft physiology and stability 
as paramount events in trespassing the thin borderline that separates normal and 
pathological aging [158].
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6. Conclusions
In summary, we may conclude that lipid rafts are the neurobiological locus for the 
wealth of alterations involved in the molecular pathophysiology of Alzheimer’s dis-
ease. Severe changes in the lipid matrix of lipid rafts represent the seminal event in the 
pathogenesis of Alzheimer’s disease. These early changes, that selectively affect corti-
cal structures altered in AD, have a profound impact on physicochemical properties 
of lipid raft which serves a favorable environment for the abnormal neuronal physiol-
ogy, especially for the interaction of secretases and APP to trigger the amyloidogenic 
processing of APP and amyloid burden. This review argues in favor of lipid rafts 
dyshomeostasis representing a foundational effect on the onset and progression of this 
devasting disease, and opens the possibility for new pharmacological approaches and 
therapeutic windows to halt the initiation of this neurodegenerative disease.
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